BIOMAT Database Logo BIOMAT Database Logo

Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma. 2018

Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
Hospices Civils de Lyon, Department of Dermatology, Lyon Sud University Hospital, Pierre Bénite, France.

UI MeSH Term Description Entries
D007414 Intestinal Neoplasms Tumors or cancer of the INTESTINES. Cancer of Intestines,Intestinal Cancer,Cancer of the Intestines,Intestines Cancer,Intestines Neoplasms,Neoplasms, Intestinal,Cancer, Intestinal,Cancer, Intestines,Cancers, Intestinal,Cancers, Intestines,Intestinal Cancers,Intestinal Neoplasm,Intestines Cancers,Intestines Neoplasm,Neoplasm, Intestinal,Neoplasm, Intestines,Neoplasms, Intestines
D007421 Intestine, Small The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM. Small Intestine,Intestines, Small,Small Intestines
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009382 Neoplasms, Unknown Primary Metastases in which the tissue of origin is unknown. Neoplasm Metastasis, Unknown Primary,Neoplasms, Occult Primary,Occult Primary Neoplasms,Unknown Primary Tumors,Unknown Primary Neoplasm Metastasis,Unknown Primary Neoplasms,Neoplasm, Occult Primary,Neoplasm, Unknown Primary,Occult Primary Neoplasm,Primary Neoplasm, Occult,Primary Neoplasm, Unknown,Primary Neoplasms, Occult,Primary Neoplasms, Unknown,Primary Tumor, Unknown,Primary Tumors, Unknown,Tumor, Unknown Primary,Tumors, Unknown Primary,Unknown Primary Neoplasm,Unknown Primary Tumor
D003875 Drug Eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. Dermatitis Medicamentosa,Dermatitis, Adverse Drug Reaction,Maculopapular Drug Eruption,Maculopapular Exanthem,Morbilliform Drug Reaction,Morbilliform Exanthem,Drug Eruption,Drug Eruption, Maculopapular,Drug Eruptions, Maculopapular,Drug Reaction, Morbilliform,Drug Reactions, Morbilliform,Eruption, Drug,Eruption, Maculopapular Drug,Eruptions, Drug,Eruptions, Maculopapular Drug,Exanthem, Maculopapular,Exanthem, Morbilliform,Exanthems, Maculopapular,Exanthems, Morbilliform,Maculopapular Drug Eruptions,Maculopapular Exanthems,Morbilliform Drug Reactions,Morbilliform Exanthems,Reaction, Morbilliform Drug,Reactions, Morbilliform Drug
D003882 Dermatomyositis A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) Polymyositis-Dermatomyositis,Dermatomyositis, Adult Type,Dermatomyositis, Childhood Type,Dermatopolymyositis,Juvenile Dermatomyositis,Juvenile Myositis,Adult Type Dermatomyositis,Childhood Type Dermatomyositis,Dermatomyositis, Juvenile,Myositis, Juvenile,Polymyositis Dermatomyositis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma.
August 2020, Dermatology and therapy,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.
July 2016, Annals of oncology : official journal of the European Society for Medical Oncology,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
December 2018, Melanoma research,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma.
July 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
November 2016, Pharmacotherapy,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma.
August 2021, The Australasian journal of dermatology,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma.
March 2018, JAAD case reports,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
A rapid response to pembrolizumab in a patient with metastatic melanoma.
March 2017, Immunotherapy,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
March 2019, Endocrinology, diabetes & metabolism case reports,
Mathilde Berger, and Anne-Lise Legeay, and Sabrine Souci, and Nathalie Streichenberger, and Luc Thomas, and Stéphane Dalle
Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
April 2019, Investigational new drugs,
Copied contents to your clipboard!